Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset

Bibliographic Details
Main Author: Figueiredo-Campos, Patricia
Publication Date: 2020
Other Authors: Blankenhaus, Birte, Mota, Catarina, Gomes, Andreia, Serrano, Marta, Ariotti, Silvia, Costa, Catarina, Nunes-Cabaço, Helena, Mendes, António M., Gaspar, Pedro, Pereira‐Santos, M. Conceição, Rodrigues, Fabiana, Condeço, Jorge, Escoval, M. Antonia, Santos, Matilde, Ramirez, Mário, Cristino, José Melo, Simas, J Pedro, Vasconcelos, Eugenia, Afonso, Ângela, Veldhoen, Marc
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10451/47273
Summary: © 2020 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
id RCAP_aa0b0b490161de09ccfe5e65cea0df98
oai_identifier_str oai:repositorio.ulisboa.pt:10451/47273
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onsetCOVID-19SARS-CoV-2SeroprevalenceNeutralizing antibodies© 2020 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.SARS-CoV-2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia-COVID-19-but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of 6 months following COVID-19 onset. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff, and 198 post-COVID-19 volunteers. Anti-SARS-CoV-2 antibody responses follow a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce subsequently, the ability to detect anti-SARS-CoV-2 IgG antibodies remained robust with confirmed neutralization activity for up to 6 months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.We like to acknowledge the funding from the European Union H2020 ERA project (No 667824 – EXCELLtoINNOV) and the Fundação para a Ciência e a Tecnologia (FCT) to P.F‐C. (SFRH/BD/131605/2017), PTDC/MED‐IMU/28003/2017, and research4COVID19 (no. 231_596873172, Generating SARS‐CoV2 seroconversion assay and no. 729, High‐throughput SARS‐CoV2 neutralizing antibodies assessment), with additional support by Sociedade Francisco Manuel dos Santos.John Wiley & Sons, Inc.Repositório da Universidade de LisboaFigueiredo-Campos, PatriciaBlankenhaus, BirteMota, CatarinaGomes, AndreiaSerrano, MartaAriotti, SilviaCosta, CatarinaNunes-Cabaço, HelenaMendes, António M.Gaspar, PedroPereira‐Santos, M. ConceiçãoRodrigues, FabianaCondeço, JorgeEscoval, M. AntoniaSantos, MatildeRamirez, MárioCristino, José MeloSimas, J PedroVasconcelos, EugeniaAfonso, ÂngelaVeldhoen, Marc2021-04-07T12:23:05Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/47273engEur J Immunol. 2020 Dec;50(12):2025-20400014-298010.1002/eji.2020489701521-4141info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-17T14:31:45Zoai:repositorio.ulisboa.pt:10451/47273Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T03:14:19.730855Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
title Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
spellingShingle Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
Figueiredo-Campos, Patricia
COVID-19
SARS-CoV-2
Seroprevalence
Neutralizing antibodies
title_short Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
title_full Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
title_fullStr Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
title_full_unstemmed Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
title_sort Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset
author Figueiredo-Campos, Patricia
author_facet Figueiredo-Campos, Patricia
Blankenhaus, Birte
Mota, Catarina
Gomes, Andreia
Serrano, Marta
Ariotti, Silvia
Costa, Catarina
Nunes-Cabaço, Helena
Mendes, António M.
Gaspar, Pedro
Pereira‐Santos, M. Conceição
Rodrigues, Fabiana
Condeço, Jorge
Escoval, M. Antonia
Santos, Matilde
Ramirez, Mário
Cristino, José Melo
Simas, J Pedro
Vasconcelos, Eugenia
Afonso, Ângela
Veldhoen, Marc
author_role author
author2 Blankenhaus, Birte
Mota, Catarina
Gomes, Andreia
Serrano, Marta
Ariotti, Silvia
Costa, Catarina
Nunes-Cabaço, Helena
Mendes, António M.
Gaspar, Pedro
Pereira‐Santos, M. Conceição
Rodrigues, Fabiana
Condeço, Jorge
Escoval, M. Antonia
Santos, Matilde
Ramirez, Mário
Cristino, José Melo
Simas, J Pedro
Vasconcelos, Eugenia
Afonso, Ângela
Veldhoen, Marc
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Figueiredo-Campos, Patricia
Blankenhaus, Birte
Mota, Catarina
Gomes, Andreia
Serrano, Marta
Ariotti, Silvia
Costa, Catarina
Nunes-Cabaço, Helena
Mendes, António M.
Gaspar, Pedro
Pereira‐Santos, M. Conceição
Rodrigues, Fabiana
Condeço, Jorge
Escoval, M. Antonia
Santos, Matilde
Ramirez, Mário
Cristino, José Melo
Simas, J Pedro
Vasconcelos, Eugenia
Afonso, Ângela
Veldhoen, Marc
dc.subject.por.fl_str_mv COVID-19
SARS-CoV-2
Seroprevalence
Neutralizing antibodies
topic COVID-19
SARS-CoV-2
Seroprevalence
Neutralizing antibodies
description © 2020 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-04-07T12:23:05Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/47273
url http://hdl.handle.net/10451/47273
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Eur J Immunol. 2020 Dec;50(12):2025-2040
0014-2980
10.1002/eji.202048970
1521-4141
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons, Inc.
publisher.none.fl_str_mv John Wiley & Sons, Inc.
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833601637775572992

Similar Items